Expression of neurotrophins and their receptors in primary osteosarcoma

to determine the expression of neurotrophins and their tyrosine-kinase receptors in patients with osteosarcoma (OS) and their correlation with clinical outcomes. we applied immunohistochemistry to biopsy specimens of patients consecutively treated for primary OS at a single institution between 2002...

Full description

Saved in:
Bibliographic Details
Published inRevista do Colegio Brasileiro de Cirurgioes Vol. 46; no. 2; p. e2094
Main Authors Antunes, Bruno Pereira, Becker, Ricardo Gehrke, Brunetto, André Tesainer, Pavei, Bruno Silveira, de-Farias, Caroline Brunetto, Rivero, Luís Fernando da Rosa, Santos, Julie Francine Cerutti, de-Oliveira, Bruna Medeiros, Gregianin, Lauro José, Roesler, Rafael, Brunetto, Algemir Lunardi, Pagnussato, Fernando, Galia, Carlos Roberto
Format Journal Article
LanguagePortuguese
Published Brazil 09.05.2019
Subjects
Adolescent
Biomarkers, Tumor
Bone Neoplasms - mortality
Bone Neoplasms - pathology
Brain-Derived Neurotrophic Factor - analysis
Child
Child, Preschool
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Nerve Growth Factors - analysis
Osteosarcoma - mortality
Osteosarcoma - pathology
Receptor, trkA - analysis
Receptor, trkB - analysis
Reference Values
Risk Factors
Statistics, Nonparametric
Online AccessGet more information

Cover

More Information
Summary:to determine the expression of neurotrophins and their tyrosine-kinase receptors in patients with osteosarcoma (OS) and their correlation with clinical outcomes. we applied immunohistochemistry to biopsy specimens of patients consecutively treated for primary OS at a single institution between 2002 and 2015, analyzing them for expression receptors of tyrosine kinase A and B (TrKA and TrKB), neural growth factor (NGF) and brain derived neurotrophic factor (BDNF). Independently, two pathologists classified the immunohistochemical markers as negative (negative or weak focal) or positive (moderate focal/diffuse or strong focal/diffuse). we analyzed data from 19 patients (10 females and 9 males), with median age of 12 years (5 to 17.3). Tumors' location were 83.3% in the lower limbs, and 63.2% of patients had metastases at diagnosis. Five-year overall survival was 55.3%. BDNF was positive in 16 patients (84%) and NGF in 14 (73%). TrKA and TrKB presented positive staining in four (21,1%) and eight (42,1%) patients, respectively. Survival analysis showed no significant difference between TrK receptors and neurotrophins. primary OS samples express neurotrophins and TrK receptors by immunohistochemistry. Future studies should explore their role in OS pathogenesis and determine their prognostic significance in larger cohorts.
ISSN:1809-4546